SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/16/19 Anavex Life Sciences Corp. 10-K 9/30/19 45:3.2M Electro Filings LLC/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 583K 2: EX-21.1 Subsidiaries List HTML 13K 3: EX-23.1 Consent of Experts or Counsel HTML 14K 4: EX-31.1 Certification -- §302 - SOA'02 HTML 20K 5: EX-31.2 Certification -- §302 - SOA'02 HTML 20K 6: EX-32.1 Certification -- §906 - SOA'02 HTML 16K 41: R1 Document and Entity Information HTML 54K 22: R2 Consolidated Balance Sheets HTML 65K 17: R3 Consolidated Balance Sheets (Parenthetical) HTML 29K 29: R4 Consolidated Statements of Operations HTML 58K 42: R5 Consolidated Statements of Cash Flows HTML 59K 23: R6 Consolidated Statement of Changes in Stockholders' HTML 61K Equity 18: R7 Business Description and Basis of Presentation HTML 44K 30: R8 Summary of Significant Accounting Policies HTML 57K 40: R9 Other Income HTML 21K 33: R10 Equity Offering Agreements HTML 29K 44: R11 Commitments HTML 68K 25: R12 Income Taxes HTML 45K 21: R13 Summary of Significant Accounting Policies HTML 98K (Policies) 32: R14 Business Description and Basis of Presentation HTML 34K (Tables) 43: R15 Commitments (Tables) HTML 62K 24: R16 Income Taxes (Tables) HTML 41K 20: R17 Business Description and Basis of Presentation HTML 64K (Details) 31: R18 Business Description and Basis of Presentation HTML 23K (Details Narrative) 45: R19 Summary of Significant Accounting Policies HTML 17K (Details Narrative) 27: R20 Other Income (Details Narrative) HTML 26K 16: R21 Equity Offering Agreements (Details Narrative) HTML 55K 35: R22 Commitments (Details) HTML 37K 38: R23 Commitments (Details 1) HTML 56K 26: R24 Commitments (Details 2) HTML 20K 14: R25 Commitments (Details 3) HTML 25K 34: R26 Commitments (Details Narrative) HTML 62K 37: R27 Income Taxes (Details) HTML 22K 28: R28 Income Taxes (Details 1) HTML 36K 13: R29 Income Taxes (Details 2) HTML 40K 19: R30 Income Taxes (Details Narrative) HTML 37K 15: XML IDEA XML File -- Filing Summary XML 71K 36: EXCEL IDEA Workbook of Financial Reports XLSX 51K 7: EX-101.INS XBRL Instance -- avxl-20190930 XML 642K 9: EX-101.CAL XBRL Calculations -- avxl-20190930_cal XML 81K 10: EX-101.DEF XBRL Definitions -- avxl-20190930_def XML 244K 11: EX-101.LAB XBRL Labels -- avxl-20190930_lab XML 571K 12: EX-101.PRE XBRL Presentations -- avxl-20190930_pre XML 405K 8: EX-101.SCH XBRL Schema -- avxl-20190930 XSD 92K 39: ZIP XBRL Zipped Folder -- 0001731122-19-000784-xbrl Zip 79K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Anavex Life Sciences Corp.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-218292, No. 333-207600 and No. 333-232550) and Form S-8 (No. 333-219934) of Anavex Life Sciences Corp. and subsidiaries of our reports dated December 16, 2019 relating to the consolidated financial statements, and the effectiveness of Anavex Life Sciences Corp.’s internal control over financial reporting, which appear in this Annual Report on Form 10-K. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of Anavex Life Sciences Corp.’s internal control over financial reporting as of September 30, 2019.
/S/ BDO USA, LLP
New York, New York
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 12/16/19 | None on these Dates | ||
For Period end: | 9/30/19 | |||
List all Filings |